Goodwin Procter LLP advised CRISPR Therapeutics AG on the deal.

CRISPR Therapeutics completed $517.5 million follow-on offering, including the full exercise of the underwriters’ option to purchase additional shares, of an aggregate of 7,392,857 common shares at a price to the public of $70.00 per share. Aggregate gross proceeds were approximately $517.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.

CRISPR is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

The Goodwin team was led by Rob Puopolo (Picture), Seo Salimi, John Mei, Carly Ward, and Navid Wheeler, and included Stephanie Philbin, Dan Karelitz, Alex Plaum, Brian Fairchild, and Ettore Santucci.

Involved fees earner: Brian Fairchild – Goodwin Procter; Daniel Karelitz – Goodwin Procter; John Mei – Goodwin Procter; Stephanie Philbin – Goodwin Procter; Alexander Plaum – Goodwin Procter; Robert Puopolo – Goodwin Procter; Seo Salimi – Goodwin Procter; Ettore Santucci – Goodwin Procter; Carolyn Ward – Goodwin Procter; Navid Wheeler – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: CRISPR Therapeutics AG;

Source link